The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Newer treatment options in PV and how the therapeutic landscape is evolving
Lindsay Rein, MD, Duke University Medical Center, Durham, NC, provides an overview of her talk on the evolving treatment landscape in polycythemia vera (PV), highlighting how an improved understanding of disease biology has transformed therapy development. Dr Rein mentions the exciting MAJIC-PV (NCT01901432) study, which correlated outcomes such as event-free survival (EFS) and overall survival (OS) to molecular responses in ruxolitinib-treated patients. Additionally, Dr Rein comments on promising novel therapies, including LSD1 inhibitors, HDAC inhibitors, and hepcidin memetics, such as rusfertide. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, Novartis, Sumitomo, Sobi, Morphsys, Incyte.
